Neoplasms – Talk Bio

Bristol Myers Squibb Completes $4.8 Billion Acquisition of Mirati Therapeutics

14 hours ago talkbio0Tagged Acquisition, KRAS NP_004976.2:p.G12C, Myers Squibb, Neoplasms

Bristol Myers Squibb; Mirati Therapeutics; acquisition; $4.8 billion; KRAZATI; oncology; KRAS G12C

AbbVie Pays $650M Upfront to RemeGen for PD-1/VEGF Bispecific RC148 Rights Outside China

3 days ago talkbio0Tagged AbbVie, Antibodies, Bispecific, Neoplasms, PD-1/VEGF, RC148, RemeGen

AbbVie; RemeGen; RC148; PD-1/VEGF; bispecific antibody; oncology; licensing deal; $650M; $5.6B

Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026

5 days ago talkbio0Tagged Aktis, AKTS, Biotech IPOs, bounce, Capital Markets, CD276 gene, Eli Lilly backing, IPO, NECTIN4 gene, Neoplasms, Radiopharmaceuticals, Window (physical object)

Aktis Oncology IPO; AKTS; 2026 biotech IPOs; IPO bounce; radiopharmaceuticals; Eli Lilly backing; biotech capital markets; Nectin-4; B7-H3; IPO window 2026

Speculation builds about a multibillion-dollar takeout of Revolution Medicines

5 days ago talkbio0Tagged AbbVie, Acquisition, daraxonrasib, financial, J.P. Morgan Healthcare Conference, Merck, Neoplasms, RAS-driven cancers, Revolution Medicines, rumors, RVMD, takeover talks, Wall Street Journal

Revolution Medicines; RVMD; Merck; AbbVie; takeover talks; acquisition rumors; buyout speculation; Financial Times report; Wall Street Journal; J.P. Morgan Healthcare Conference; multibillion-dollar deal; oncology; RAS-driven cancers; daraxonrasib

Roche returns to Chinese biotech MediLink for another ADC pact

6 days ago talkbio0Tagged Antibody-Drug Conjugates, CD276 gene, China, Neoplasms, Platform, Roche (company), Small cell carcinoma of lung, small-cell lung cancer, Solid Neoplasm, therapeutic autologous dendritic cells, TMALIN, YL201

Roche; MediLink Therapeutics; YL201; antibody-drug conjugate; ADC; B7-H3; TMALIN platform; small-cell lung cancer; SCLC; solid tumors; licensing deal; oncology; China biotech

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

6 days ago talkbio0Tagged Autoimmune, cardiometabolic, Eli, Eli Lilly, Immunotherapy for cancer, InduPro * *, Inflammatory disorder, M&A, Neoplasms, Neuroinflammation, NLRP3 inhibitors, Obesity, Ventyx Biosciences, VTX3232, VTX958

Eli Lilly; Lilly; Ventyx Biosciences; InduPro; inflammatory diseases; oncology; NLRP3 inhibitors; tamuzimod; VTX2735; VTX3232; VTX958; autoimmune; obesity; cardiometabolic; neuroinflammation; M&A; biotech deal; cancer immunotherapy

Exclusive: Charles Fuchs departs Roche to become Chief Medical Officer at Tubulis, steering ADC pipeline after $401M Series C

7 days ago talkbio0Tagged Antibody-Drug Conjugates, Cambridge office, Charles Fuchs, Chief Medical Officer, genentech, Hematology (discipline), NaPi2b, Neoplasms, pipeline, Roche (company), Series C financing, Solid Neoplasm, therapeutic autologous dendritic cells, TPBG gene, TUB-030, TUB-040, Tubulis

Charles Fuchs; Tubulis; Roche; Genentech; chief medical officer; antibody-drug conjugates; ADC pipeline; TUB-040; TUB-030; Series C financing; oncology; hematology; solid tumors; NaPi2b; 5T4; Cambridge office

Syncromune Appoints Dr. Stephen P. Dale as Chief Medical Officer

1 week ago talkbio0Tagged Appointments, Biological Factors, Chronic multifocal osteomyelitis, Neoplasms, Stephen P. Dale, SYNC-T, Syncromune

Syncromune; Stephen P. Dale; CMO; appointment; oncology; SYNC-T; biopharmaceutical

Aktis Oncology Targets $181M-$209M in First Biotech IPO of 2026

1 week ago talkbio0Tagged Aktis, IPO, methionine, Neoplasms, Radiopharmaceuticals

Aktis Oncology; IPO; biotech; radiopharmaceutical; 2026; $181M; $200M

Spotlight On: Five key oncology stories to watch in 2026

1 week ago talkbio0Tagged 2026, Antibody-Drug Conjugates, cancer research trends, CAR-T, Cell Therapy, Liquid Biopsy, Lymphocytes, Tumor-Infiltrating, mRNA cancer, Neoplasms, oncology decisions, precision oncology, Radiopharmaceuticals, T-Cell Receptor, United States Food and Drug Administration, Vaccines

oncology 2026; cancer research trends; FDA oncology decisions 2026; antibody-drug conjugates; radiopharmaceuticals; liquid biopsy; mRNA cancer vaccines; AI in oncology; cell therapies CAR-T TIL TCR; precision oncology